Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Telos' Decentralization Rivals that of Bitcoin and Ethereum

Telos Foundation

Telos Blockchain (ticker: TLOS), the world’s most robust and decentralized ESG compliant layer 1 platform and home to the world's fastest, highest capacity EVM (tEVM), derives credible neutrality and decentralization from at least 42 equally distinct validating nodes compared to the much smaller number of major mining pools securing Bitcoin and Ethereum. After a thorough competitive analysis comparing Telos’ decentralization to the decentralization of many of the other top Layer 1 chains, the Foundation has confirmed its assumptions. Based on validator equality and crucial factors regarding architecture and finances, the team confirmed that Telos is indeed one of the leading chains regarding credible neutrality and decentralization. As mining pools lack equality, massive node counts become irrelevant: As depicted in the pie charts above, Telos, via its governance, has maintained an equitable distribution amongst all its active validators and Bitcoin and Ethereum have not. Instead, the mining pools of both Bitcoin and Ethereum have now become centralized. The hypothesis is that over the years the well-funded pools have overtaken the little ones. Despite the substantial number of nodes, to be a credibly neutral peer-to-peer network, the network must also sustain even splits in validator power / responsibilities. Without this equality, the insulating strengths of decentralized peer-to-peer networking becomes significantly degraded. A decentralized network made up of equitable validators adds a powerful layer of insulation against multiple scenarios. For example, a multi-government coalition could potentially implement disruptive regulations or restrictions on blockchain. If only a handful of validators / mining pools need to be targeted, it becomes much easier for those governments to impose their will and degrade the insulation that a peer-to-peer network is supposed to provide. In fact, an event far smaller than this could instantly interrupt some chains from operating as they intended. However, the problem is not just limited to government interference. It is also the potential of a coalition amongst the validator majority that threatens the decentralization and stability of a chain. Despite having many nodes, it appears that for Bitcoin it would take only ~5 large mining pools to form a majority, only ~4 for Ethereum and 22 for Telos (as depicted in the pie charts above). Aside from this significant (4x to 5x) difference, it is also worth noting that the community fairly votes the Telos validators into active slots vs Bitcoin / Ethereum in which the mining pool’s principles are anonymous and can simply buy their way into a majority position. Hence, the centralization and lack of credible neutrality that has now formed. Credible neutrality cannot exist in an environment in which control and influence is exerted by small groups of well-funded people. This move towards validator centralization also leads to neutrality questions that are impossible to answer. For example, are the validator majorities' ambitions in line with what is best for the chain or themselves? To put the potential gravity of this into perspective one needs to understand that the principal/s of a majority sized mining pool can easily be a crime syndicate, and no one would know about it due to the anonymity. In fact, all the major mining pools can hypothetically be owned by crime syndicates, and no one would ever know. In contrast to this, with chain-governed validator equality and ongoing fair community voting, these credibility and neutrality questions are simply non-existing issues. In fact, all these chain degrading scenarios are exactly what the Telos architecture and governance have insulated against. As a chain’s validator network becomes unequal in size; the more it will move towards centralization, the more its neutrality will become biased and the more these chain breakdown scenarios may become a reality. Insider allocation cost blockchain’s their credible neutrality: Being that Telos was a 100% bootstrap project (95% of the coins airdropped to the community, 5% were used as equal pay to the almost 150 contributors, no insider handouts, and no ICO), the team already knew that its insider allocation was at the same level as Bitcoin’s beginnings, zero. Telos is the only L1 chain besides Bitcoin to have ever reached this stage of maturity while still maintaining zero insider allocation. All the other L1 chains are believed to be centralized and unable to become credibly neutral public infrastructure due to their insider allocation (click here to see). With this being noted, these chains will most likely never be utilized by governments as a legal tender and dApps depending on this infrastructure will never be 100% insulated by the full power of credible neutrality and decentralization. Telos Decentralization: Since its inception, the validators of the Telos Blockchain are both equally sized and regionally / globally diversified. Plus, no ungoverned wallet is known to hold more than 2% of the chain. From chain architecture to finances, decentralization and neutrality are of the highest priority for the chain. Over the last 4 years, Telos has grown into a truly utopian blockchain option for both private and public infrastructure. It is ludicrously fast, very inexpensive, extremely energy efficient, credibly neutral, non-congested, super easy to deploy on and the only chain that fully insulates the public from the front running / MEV that is plaguing Ethereum. Decentralization Highlights: Telos is the only third generation layer 1 blockchain to have never done an ICO [initial coin offering] and this non-action alone insulates the chain greatly regarding insider collusion and the SEC security law suits. Telos, at its inception, electively chose to stay a bootstrap project and rise in the same fashion as Bitcoin. All other third generation layer 1 chains (including Ethereum) have done ICOs and will more than likely be forced to file with the SEC as securities. The former and current SEC Chairman have both expressed that every ICO [initial coin offering] they have seen are indeed securities, that they have jurisdiction, and that federal securities laws apply. The validating architecture of other networks might be structured via peer-to-peer architecture, but they are not credibly decentralized due to the distribution of monetary / voting / validating power. Again, insider allocation is non-existent and as you can see above in the pie charts depicting validator decentralization, Telos Validators are proportionally equal. Telos governance has the fairest voting system in existence, called Telos Decide. It is tamper-proof and secured by the Tlos coins that investors own. A coin holder can vote on behalf of the coins they hold and rely on outcomes that do not require any further human involvement. No other Layer 1 offers this level of automated community fairness. Especially because the Telos governance documents may be dynamically amended by the votes of the coin holders in a process that is entirely controlled by on-chain smart contracts. Governments, investors, dApp creators, and end users need not forget that the fundamental features which bring the most value to blockchain are credible neutrality and decentralization. With credible neutrality and decentralization the following attributes are all significantly enhanced: Utility Redundancy Security / Trust Individual Financial Independence dApp Sovereignty Fair Voting Legal Tender The actions and inactions of Telos are driven by the belief that the public and private sectors require credibly neutral blockchain infrastructure in a third-generation capable format. Credible neutrality, ludicrously fast speeds, energy efficiency, and super low-cost transactions make Telos the perfect crypto currency for the global internet and for the people. About Telos Live since 2018, Telos Blockchain (ticker: Tlos) is a third-generation smart contract platform that offers compatibility with Solidity, Vyper and Native C++ smart contracts. Telos provides full EVM/Solidity support with fixed low-cost gas fees and no front running. Uniquely, Telos also offers a path to fee-less transactions via its robust native C++ smart contract support. Utilizing less than 0.000002 kWh per transaction, the chain can sustainably support hundreds of millions of transactions per day, produce blocks in 0.5 second intervals on a first-in-first-out basis (eliminating front running on the network) and securely validate transactions via a credibly neutral and globally decentralized block producer network. The Telos Blockchain has the throughput needed to facilitate and scale the thriving Metaverse / Web 3.0 better than any other blockchain. Its performance is unrivaled in the industry and was purpose-built to offer speed, scalability, cost-effectiveness, credible decentralization, and end-user fairness. Telos, harnesses its power by utilizing tight C++ on the frontend and a custom WASM runtime environment on the backend. About The Foundation The Telos Foundation is a Decentralized Autonomous Organization established as a promotional and funding body to advance the Telos Blockchain Network and provide support to network applications. Contact Details The Team hello@telosfoundation.io Company Website https://www.telos.net/

April 20, 2022 10:07 AM Eastern Daylight Time

Video Image

News Release

Premium Delta 8 And CBD Products Launched By Budpop - A Bird’s Eye View At Hemp Products

Blue Ribbon Group

BudPop's scorching, booming arrival into the marijuana sector has had a big impact. Even though BudPop has only been in business for a short time, they have established a huge consumer base, with thousands upon thousands of delighted customers. BudPop sells only Delta 8 and CBD products and essential accessories. In 2021, a group of professionals and fans developed an all-natural, chemical-free, incredibly effective substance. Certain players had already infiltrated the mass market before entering the cannabis industry through online sales. BudPop had a hard challenge. BudPop has become one of the best delta 8 brands in the entire cannabis market due to this strategy, surpassing its competitors. BudPop is one of the most popular firms in the hemp industry, with a wide variety of products to choose from. The quality of their ingredients and the potency of their products have made them a household name. The company has released CBD gummies in three flavors with the same quality as other BudPop products. A wide range of CBD and Delta 8 edibles are on the market, but CBD gummies are by far the most popular. In addition to being easy to eat, gummies are also tasty. The gummies are also available in various flavors, and the user can eat them without causing any discomfort to others. These gummies are made in the U.S with high-quality ingredients. They come in a variety of tantalizing flavors and are suitable for vegans. To combat stress and anxiety, CBD + Ashwagandha is a potent combination that can be taken at any time of the day or night because it boosts mental clarity and physical energy. After a long and exhausting day, CBD + CBN gummies are a great way to wind down and unwind. Improves sleep quality and wakes users up feeling revitalized. It's hard to go wrong with either of these flavors. A new CBD gummy bear line from BudPop has been a big success, with three distinct flavors to choose from. Since they've received a large number of orders in a short time, they've managed to meet the expectations of their customers. In the CBD + CBG & Turmeric version, turmeric's powerful anti-inflammatory and digestive properties are combined with a delicious orange flavor. High-quality black pepper extract and organic turmeric root powder go into making this recovery drink, which aids in muscle repair after a workout. Customers can enjoy BudPop CBD gummies without having to worry about their wallets. Those looking to save funds without sacrificing the product's quality can do so without hesitation. Regular users can save money by subscribing weekly or monthly or purchasing bundles. They can also save money by purchasing multiple models at the same time. First-time customers can get a discount on their first purchase at BudPop, which is a nice perk. Thirty potent CBD gummies are included in every bottle. Free shipping is available to all customers, and orders are processed within 48 hours. These CBD gummies have third-party lab reports on the brand's official website for those who have doubts. The ingredients in BudPop gummies have not been tampered with in any way, so they are completely safe to eat. Customers can buy with confidence thanks to the company's 30-day money-back guarantee policy, which allows them to do so without fear. BudPop is a newcomer to the hemp industry, but it has gained a lot of popularity in a short amount of time. In addition to being effective, their products are also safe to ingest. To ensure that customers enjoy their shopping experience, the company focuses on customer service. Their CBD gummies can easily compete with other products in the same price range. BudPop sells CBD and Delta 8 products devoid of chemicals and preservatives and can be consumed by vegans and non-vegans alike. The use of CBD and Delta 8 in treating anxiety disorders such as post-traumatic stress disorder (PTSD) and social anxiety disorder may be beneficial. BudPop CBD products are composed of components that might help you relax, de-stress, and concentrate better. Each dose comprises 50 milligrams of CBD, and each bottle has 1500 milligrams of CBD. They use organic coconut oil, hemp-derived CBD, peppermint oil, water, sucrose, and natural terpenes to manufacture BudPop products. Each BudPop Gummy contains 25mg of CBD and Ashwagandha, sufficient to reduce anxiety. Natural mixed fruit tastes are employed to sweeten the product, which is mostly made of organic hemp. Even if you are a vegan, you can consume these gummies. The gummies were well-received by customers, and many claim that the gummies keep them calm and focused. The product has boosted the company's fame to new heights. In the words of Danny G. Rose, "I adore the natural flavor of these CBD gummies. Their strength is something I rely on when I'm under pressure." According to David L.'s assertions, "To my surprise, these CBD gummies were just as good as the BudPop products I've used for years. They exceeded my expectations, and I intend to experiment with additional flavors in the future." Jennifer Harner Says “I love this gummy so much! My insomnia has worsened as I've gotten older. Even though I'm legally allowed to use Ambien, I try to avoid doing so regularly. No over-the-counter sleep aid has worked for me so far. There are no fakes in this gummy! When I take one, I fall asleep quickly and soundly. Taking it for arthritis pain, my husband says it lowers his pain threshold significantly. Try it out; you won't be sorry!” Because BudPop has never compromised product quality, their customers consistently give them high ratings and recommendations. They have once again met or exceeded the expectations of their customers. Ordering CBD gummies from the brand's official website is possible for those who haven't yet had a chance to do so. There are a lot of Millennials in the cannabis market, and BudPop is aware of this demographic. The millennial generation infused their products with new and exciting flavors to make their edibles and oils more appealing. These Delta-8 gummies have elevated BudPop's brand to a new level. Premium quality ingredients are used in the gummies manufactured in the United States. Customers can enjoy these gummies without having to worry about their dietary preferences. They are also completely cruelty-free, which is a huge plus. Customers can choose from two delicious flavors, each with a distinct flavor. Customers want more flavors like Strawberry Gelato and Blue Dream, which are currently available. They have a calming effect and are extremely potent. 25 mg of potency per gummy is contained in one container. Compared to Delta-9 THC products, their effects are more mellow, and customers can expect a more relaxing experience with them. Using this product regularly has provided relief for many customers suffering from chronic pain. It's safe to try these gummies because they don't contain any extraneous fillers. For Delta 8 edibles, BudPop is one of the most well-known names in this category. The gummies have gotten rave reviews from customers, and many consider them to be the best product they've ever used. It's rare for users to come across these kinds of deals elsewhere. The brand's products are all compliant with the 2018 farm bill's requirements for legal law compliance. As a result, THC content in the products is kept to less than 0.3 percent naturally. The law has the authority to take action against people who purchase products with more THC content than this, and users should avoid doing so. All of the brand's other products are also free of harmful chemicals. Third-party lab test reports can also be viewed on the company's website. These reports can be checked by anyone who doubts the product's quality. As Brian R. Michell puts it, "I just received my first one, and I'm already thinking about placing another order. The flavor is out of this world, and I was blown away by the quality." Based on what Leon K. George has to say, "My anxiety was nonexistent following the consumption of these gummies, despite their potency. The flavor instantly smote me, and I can't wait to try the strawberry variety." That is the opinion of Robert L "I ordered the blueberry flavor after a recommendation from a friend. I love the gummies because they make me feel calm and relaxed. Now is the time to experiment with the other flavors." Antonia Sweeney Says, “This product has exceeded my expectations. It makes things a lot simpler. For those who move frequently, it would be nice to call a phone number to update our delivery information. There are ways to improve the website. Nonetheless, I'm a big fan of this company because they've always come to my aid.” Customers can select from a broad range of mouthwatering flavors when purchasing any BudPop product on the market today. Although their products aren't cheap, the prices aren't excessive. They've found success by offering high-quality products at competitive prices. Subscription plans and bundle packs can save a lot of money for regular users, and they often have attractive discounts and offers for them. Contact Details Riya Tyagi +1 818-468-5567

April 20, 2022 07:42 AM Eastern Daylight Time

GROUNDWORK BIOAG’S GLOBAL COMMERCIAL BUSINESS EXPANDS TO CHINA

Groundwork BioAg

As part of its steady global expansion, Groundwork BioAg opened a representative office in China to serve one of the world’s leading agriculture markets, with approximately 127 million hectares of harvested farm cropland. The company’s flagship BioPlatform - Rootella ® - will be available to farmers across four of the world’s major agricultural markets: the United States, Brazil, India, and now China. “As food demands continue to intertwine with climate pressures on a global scale, we look forward to helping Chinese farmers reduce the negative impact of synthetic fertilizers, particularly phosphorus, while establishing more resilient crop production and permanent carbon sequestration across millions of hectares in China,” said Dr. Yossi Kofman, co-founder and CEO of Groundwork BioAg. “As the ‘Queen of Biologicals,’ highly concentrated mycorrhizal inoculants enable all other innovation to ensure conventional farmers can regenerate their soil, sequester carbon, and grow a bountiful, more sustainable harvest.” Located in the city of Sanya in the agricultural hub of Hainan Province, the representative office will act as Groundwork BioAg’s business center for customers and partners across China. Mr. Shu Yang, an experienced manager in agriculture and biologicals, will lead the office. The new business center will enable the company to help farmers enact China’s 14th Five-Year National Agriculture Green Development Plan. Announced in October of 2021, the Plan identified resource protection, pollution control, restoration of agricultural ecology, and the development of low-carbon agricultural industrial chains as key goals to be achieved by 2025. According to the FAO, China is among the world’s largest agricultural producers of cereals, cotton, fruit, and vegetables, and remains second only to the United States in corn production. Groundwork BioAg is the first mycorrhiza producer that can support large-scale agriculture based on its unique production capabilities. Applied on more than one million acres in 2021, Rootella is based on naturally robust strains of mycorrhizal fungi that are symbiotic with 90% of plant species, offering the most efficient and effective solution to diverse crops and growing areas. Kofman said, “China is a cornerstone of our global plan and critical to delivering on our promise to help reduce the impact of climate change while ensuring global food security.” Groundwork BioAg has established commercial operations across most of the world’s major agricultural markets, including the United States, Brazil, China, India, Canada, Europe, Ukraine, and New Zealand. In March, Groundwork BioAg® was named by Fast Company as one of the World’s Most Innovative Food Companies for 2022 for tackling grand challenges facing humankind today: food security, soil health, and climate change. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

April 20, 2022 06:30 AM Central Daylight Time

Genomic Life to Present at Business Group on Health’s Annual Conference

Genomic Life

Genomic Life, a leading genome benefit management company with a mission of providing innovative benefit services to employers, will present at the Business Group on Health’s annual conference. The Business Group on Health’s annual conference brings together experts and employers related to health benefits and health care policies. This year’s theme is “Collaborating on the Future of Health and Well-Being,” and will be held between April 19-21, 2022 at the Renaissance Nashville Hotel. The company has an over-arching goal of making affordable clinical-grade genetic testing available to everyone, genetic testing plays an essential role in managing proactive health, informing individuals of their health risks and pre-existing conditions they would not have known about otherwise. Genomic Life helps facilitate the most appropriate testing at the highest quality labs with access to clear results and expert genetic counseling. These services help patients and their physicians turn those genetic insights into precise and timely actions. On Tuesday, April 19, 2022, from 9 – 11 a.m. CDT, Genomic Life will host an invite-only breakfast event panel at the nearby historic Union Station Nashville Hotel. Guests can also join virtually via Zoom. The panel will be focused on the future of proactive health and the power of genetic testing, hosted and moderated by WKRN-TV News anchor Nikki Burdine of “Good Morning Nashville,” and will feature Genomic Life executives, Karen Ferrell, MBA (Chief Executive Officer); Randy Scott, PhD (Executive Co-Chairman); Tod Klingler, PhD (Head of Product and Innovation); Robert Green, MD, MPH (Medical and Clinical Advisor); and Noël Rihm Obourn (Chief Commercial Officer). “Health technology is accelerating at a rapid pace and employers are looking for innovative ways to keep their employees healthy and engaged,” said Genomic Life CEO Karen Ferrell. “We are working with employers to take the guesswork out of genetic testing and services and help individuals and their own physicians be proactive and precise about their health and well-being.” On Wednesday, April 20, 2022 from 2-2:30 p.m. CDT, Genomic Life Executive Co-Chair Randy Scott, PhD will present a breakout session titled “Innovations in Cancer Screening and Genetic Testing” at the Business Group on Health’s annual conference. The discussion will cover how employers can leverage the power of genetic testing, precision medicine and clinical policy to strengthen their overall benefit strategy. Dr. Scott will be joined by Scott Osler, Vice President of Employer Partnerships at Grail, Inc. “Being in the field of genomics for more than 30 years, including leading the development of two revolutionary cancer diagnostic tests, I have learned a lot about how a preventive approach to healthcare can truly make a difference,” said Dr. Scott. “Our team at Genomic Life is hard at work offering comprehensive genetic testing services that span a lifetime of health benefits. We look forward to helping anyone and everyone we can make proactive, personalized and precise healthcare choices that positively impact their lives.” Genomic Life currently offers three types of genetic screenings to unlock precise and relevant healthcare insights, before illness occurs: Genetic Health Screen (GHS): A 147 gene panel that includes genetic predispositions to specific serious illnesses (cancers, cardiac, neurology, and more). Pharmacogenomics (PGx) Screen: With 25 biomarkers, this screen highlights drug-gene interactions and efficacy, informing the patient and physician which prescriptions and dosages are optimal, which are harmful, and which aren’t likely to do anything at all. Carrier Screen: A 289 gene panel that identifies critical recessive traits for those who are focused on family planning. The results include details about hereditary diseases that can be passed on to offspring and may compromise pediatric health. The results are coordinated with one’s OB-GYN to help take actions to understand and mitigate risks. Additionally, genomic insights are pivotal in the diagnosis and treatment of cancer; Genomic Life’s Cancer Guardian solution works with cancer patients and their own oncology team to facilitate best practices, ensuring that cancer patients benefit from the most precise, genomically-informed treatments. To learn more about Genomic Life and these events, please visit: https://info.genomiclife.com/lp/nbgh/. ### About Genomic Life Founded in 2017, Genomic Life is a leading genome benefit management company making affordable, clinical-grade genetic testing available to everyone, with a mission to provide innovative benefit services to employers. Genomic Life is helping close the gap in healthcare by working directly with employers to provide access to affordable genetic testing services that will enable them to seek better medical care and fill in the technology, innovation and healthcare gaps missed by health insurance companies.For more information, visit https://genomiclife.com. About Business Group on Health Business Group on Health is the leading non-profit organization representing large employers’ perspectives on optimizing workforce strategy through innovative health, benefits and well-being solutions and on health policy issues. The Business Group keeps its membership informed of leading-edge thinking and action on health care cost and delivery, financing, affordability and experience with the health care system. Business Group members include 72 Fortune 100 companies as well as large public-sector employers, who collectively provide health and well-being programs for more than 60 million individuals in 200 countries. For more information, visit www.businessgrouphealth.org. Contact Details The Hoyt Organization Cinnamon Thompson +1 310-373-0103 cthompson@hoytorg.com Company Website https://genomiclife.com/

April 19, 2022 09:00 AM Central Daylight Time

Image

TONGRENTANGCM (Hong Kong Stock Exchange: 03613) 2021 performance bucks the trend and rises Net profit reached HK$651 million, overseas business revenue increased by 30.6%

Beijing Tongrentang Chinese Medicine Co., Ltd.

HONG KONG SAR - Media OutReach - 19 April 2022 - Traditional Chinese medicine has played an important role in the prevention and control of the epidemic in recent years. In addition, the national policy has vigorously promoted the development of the industrial chain. Tongrentang, which has a brand history of more than 300 years, is actively seizing development opportunities. TONGRENTANGCM (03613), which is rooted in the Hong Kong market, revealed in its recently announced 2021 annual results announcement that its net profit reached HK$651 million, with its overseas market business revenue growing at a rapid rate of 30.6% against the trend. Both local and overseas business revenue in Hong Kong maintained high growth under the epidemic, demonstrating a stable business strategy and strong overseas development potential. The performance bucked the market and rose Strong internal and external operations The overall revenue of TONGRENTANGCM in 2021 was HK$1.556 billion, an increase of 18.3% over the same period last year, and its annual net profit reached HK$651 million, a year-on-year increase of 14.7%, of which the net profit attributable to shareholders of the listed company was HK$607 million, a year-on-year increase of 12.1%. The performance of the Hong Kong market maintained a steady growth rate, with a total revenue of HK$688 million, an increase of 26% over the previous year. The business in the overseas market achieved rapid growth, up 30.6% despite the raging global epidemic, fully demonstrating the capabilities of TONGRENTANGCM in the face of difficulties. It also reflects the potential of the Chinese medicine market overseas and in the future. Turning Crisis into Opportunity Innovating the TCM Services for International Markets Riding on the state's policies on traditional Chinese medicine business, TONGRENTANGCM seized the development opportunities, turned the crisis into an opportunity under the influence of the global epidemic, and actively explored the new ways in which traditional Chinese medicine can serve the world. Specialized in the prevention and control of the COVID19 epidemic, Tongrentang prescribed various TCM treatment programs and products for the prevention and control of the epidemic, successfully establishing a good brand reputation and image for overseas potential customers. In 2021, TONGRENTANGCM has won a number of international awards, including the 2021 Chinese Medicine Industrial Award issued by Chinese Medicine Industry Council of Australia Ltd., and the 2021 Most Influential Brand in Asia: Traditional Chinese Medicine Most Trustworthy Brand by Influential Brands, etc. Many international honors have certified the credibility and accreditation of Tongrentang's traditional Chinese medicine business overseas, which greatly enhances the confidence of foreign consumers in the brand. Fulfill social corporate responsibility Continue to contribute to epidemic prevention TONGRENTANGCM has always adhered to the corporate spirit of "Nurturing kindness and virtue, Preserving tranquility and wellness”", and have made various contributions to the society before and during the epidemic in Hong Kong. On March 2 this year, 100,000 boxes of Huoxiang Zhengqi Pian (lophanthus antifebrile tablet) worth nearly 6 million Hong Kong dollars were donated to the Hong Kong Special Administrative Region, and successively TONGRENTANGCM also donated a total value of nearly HK$700,000 of epidemic prevention and control materials, including COVID-19 Antigen Rapid Test kits, N95 anti-epidemic masks, Tongrentang traditional Chinese medicine, health drugs and food to various social welfare organizations, including Hong Kong's century-old charity organization Sik Sik Yuen, Self Help Group For the Brand Damaged, Neuro United, The Hong Kong Stroke Association, providing the social groups and the general public with the much needed anti-epidemic and health care assistance. Tongrentang donated 100,000 boxes of lophanthus antifebrile tablets worth nearly HK$6 million to the Hong Kong Special Administrative Region. Meanwhile, TONGRENTANGCM also took the initiative to offer purchase discounts on anti-epidemic products to many Chinese institutions and launched a special package of Ganoderma lucidum spore powder capsules to provide the public with more choices of anti-epidemic products. Currently, it is also planning to donate Antigen Rapid Test kits for COVID-19 to many nursing homes in Hong Kong, so that the elderly with limited mobility can also conduct self-testing, and further checking the epidemic situation in Hong Kong. Website︰ https://cm.tongrentang.com/ This press release is issued by Beijing Tongrentang Chinese Medicine Co., Ltd. Contact Details Beijing Tongrentang Chinese Medicine Co., Ltd. brandtrt@tongrentangcm.com

April 19, 2022 09:00 AM Eastern Daylight Time

Image

News Release

National Marrow Donor Program®/Be The Match® Implements Comcast Business Wavelength Services to Help Match Cancer Patients With Donors

Comcast Twin Cities

Comcast Business today announced that it is providing the National Marrow Donor Program® (NMDP)/Be The Match®, the leading global leader working to save lives through cellular therapy with a 10 Gbps optical wavelength service. The high-capacity, low-latency network solution will help Be The Match strengthen network performance, keeping its clients and employees connected, and in turn helping to ensure that transplant donors are connected to patients in need. Be The Match provides patients access to more than 39 million donors worldwide who step up to donate their marrow or blood stem cells. By connecting patients with donors and delivering life-saving cells to them, Be The Match provides cures to patients with life-threatening blood cancers and 75 blood diseases. The organization continues to lead the way in developing new cellular therapies, and in improving transplant accessibility and outcomes. Conducting this life-saving research while supporting and connecting patients to the resources they need requires a high-bandwidth, low-latency network connection. “Our network is becoming more critical, especially as we move to the cloud. If our systems aren’t available, people’s lives could be at stake,” said Robert Hanson, Vice President, Information Security, Infrastructure and Architecture, at Be The Match. “Comcast Business’ network performance has been seamless.” Comcast Business Wavelength Services deliver superior connectivity over a dense wave division multiplexing (DWDM) optical transport network with high levels of performance. Wavelength technology provides users with the ability to transport both Ethernet and non-Ethernet protocols. The point-to-point optical fiber network helps deliver data across several of Be The Match’s locations, including its headquarters in Minneapolis, its branch offices and its data center location. Since implementing Comcast Business’ services, Be The Match has been able to continue supporting patients across its various locations without concerns over network connectivity. Additionally, the reliable and fast network connections help position the organization for rising bandwidth demands and network growth, setting it up to serve its clients into the future. “To stay swift and competitive, businesses across industries continue to incorporate cloud and data center operations into their daily functions. With this will come the need for networking technology that can not only support the shifts in business today, but the continually rising bandwidth needs that the future demands,” said Wolfgang Lewis, Vice President for Comcast Business, Twin Cities Region. “Comcast Business is proud to support National Marrow Donor Program/Be The Match with its network services and do its part in making a difference in our communities.” About Comcast Business Comcast Business offers a suite of Connectivity, Communications, Networking, Cybersecurity, Wireless, and Managed Solutions to help organizations of different sizes prepare for what’s next. Powered by the nation’s largest Gig-speed broadband network, and backed by 24/7 customer support, Comcast Business is the nation’s largest cable provider to small and mid-size businesses and one of the leading service providers to the Enterprise market. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest growing providers of Ethernet services. For more information, call 866-429-3085. Follow on Twitter @ComcastBusiness and on other social media networks at http://business.comcast.com/social. About National Marrow Donor Program®(NMDP)/Be The Match® The National Marrow Donor Program®(NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With more than 30 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®(Center for International Blood and Marrow Transplant Research®)—a collaboration with Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care. Contact Details Comcast Jill Hornbacher Jill_Hornbacher@comcast.com Finn Partners Chloe Huard chloe.huard@finnpartners.com Company Website https://twincities.comcast.com/

April 19, 2022 08:00 AM Eastern Daylight Time

G Medical Innovations Holdings Ltd Announces $7.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

G Medical Innovations Holdings

TEL AVIV and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor to purchase 5,000,000 ordinary shares (or ordinary shares equivalents) in a private placement priced at-the-market under Nasdaq rules. The Company will also issue to the investor warrants to purchase up to an aggregate of 6,250,000 ordinary shares. The purchase price for one ordinary share and one warrant to purchase one ordinary share is $1.50. The warrants have an exercise price of $1.50 per ordinary share, will be immediately exercisable, and will expire five years from issuance. A.G.P./Alliance Global Partners is acting as the sole placement agent for offering. The gross proceeds from the private placement are expected to be $7.5 million before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the offering for the repayment of existing debt and working capital purposes. The private placement is expected to close on or about April 20, 2022, subject to the satisfaction of customary closing conditions. The Company also has agreed that certain warrants to purchase an aggregate of 2,400,000 ordinary shares of the Company that were issued to the investor in February 2022 will be amended to have a reduced exercise price of $1.50 per ordinary share. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares to be issued to the investors (including the ordinary shares issuable upon the exercise of the warrants) no later than 30 days after the closing and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days in the event of a "full review" by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Kobi@gmedinnovations.com Company Website https://gmedinnovations.com/

April 18, 2022 07:00 AM Eastern Daylight Time

Industrial Defender Unveils New Standalone OT Vulnerability Management Solution, Immunity by ID™

Industrial Defender

Industrial Defender, the leader in operational technology (OT) security, today announced the launch of Immunity by ID™, a new cloud-based offering that helps industrial security teams turn their OT asset inventory information into a risk-based vulnerability management program. The product is offered as a standalone solution or as an add-on within the Industrial Defender platform. Using current OT hardware and software inventory information from an asset visibility tool, CMDB or spreadsheet, this vendor-agnostic solution generates a prioritized list of vulnerabilities based on asset criticality and risk level, along with applicable patching data, to help keep critical infrastructure secure in the face of global cybersecurity threats. Immunity by ID is up and running in a matter of days, allowing users to begin their vulnerability management program immediately, and simple, transparent pricing lets them easily scale a subscription as they mature. “With the looming threat of a global cyber war, critical infrastructure organizations of all sizes are looking for straightforward solutions that rapidly deliver actionable intelligence to help them protect their essential systems,” said Peter Lund, CTO at Industrial Defender. “We created this tool to help companies better utilize the asset information they already have that may be nothing more than a data dump right now. Unlike other OT vulnerability management offerings on the market, ours is powered by an anonymized cloud, so as soon as a vulnerability is published, you'll know whether a device is at risk without waiting for the next software update.” Industrial Defender will be offering a free 14-day trial of Immunity by ID to qualified users at North American and European critical infrastructure companies through the end of May to support their efforts to shore up cybersecurity defenses. For more information, visit https://www.industrialdefender.com/immunity-by-industrial-defender/. About Industrial Defender Since 2006, Industrial Defender has been solving the challenge of safely collecting, monitoring, and managing OT asset data at scale, while providing cross-functional teams with a unified view of security. Their specialized solution is tailored to complex industrial control system environments by engineers with decades of hands-on OT experience. Easy integrations into the broader security and enterprise ecosystem empower IT teams with the same visibility, access, and situational awareness that they’re accustomed to on corporate networks. Learn more at www.industrialdefender.com. Contact Details Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

April 14, 2022 09:00 AM Eastern Daylight Time

PathPresenter Introduces ClinPx™ - A Clinical Enterprise Platform

PathPresenter

Pilot installation at The Ohio State University integrates ClinPx into Epic’s Beaker Laboratory Information System (LIS), allowing The Ohio State University (OSU) pathologists to receive, view, and sign out cases – uploaded from around the world – directly in Beaker. PathPresenter, the premier digital pathology platform for education and conferences with more than 40,000 users and 20+ institutional licenses, now presents to clinical users a best-in-class clinical enterprise platform, ClinPx. ClinPx is a custom, institution-branded, clinical enterprise platform that enables pathology consultations to be directly viewed and reported in your institution’s LIS through our proprietary backend HL7 messaging engine. It has inbuilt quality control (QC) ensuring whole slide images are of diagnostic quality and has the ability to integrate validated AI models into the scanner-agonistic viewer. ClinPx allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists as well as bidirectional communication channels for ordering stains and recuts. It also enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. This functionality brings the control and organization of the clinical workflow back to the end user. Our first pilot installation with The Ohio State University Wexner Medical Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) integrates ClinPx into Epic’s Beaker LIS, allowing pathologists at The Ohio State University to receive, view, and sign out cases uploaded from around the world directly in Beaker. “Our goal is to use ClinPix to augment OSU’s pathology clinical consultation capabilities globally. ClinPx has the ability to integrate with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate,” said Dr. Anil Parwani, vice chair of anatomic pathology at The Ohio State University College of Medicine. Rajendra Singh, co-founder of PathPresenter, added “ClinPX creates a solution to allow for the integration of digital pathology into existing workflows used by pathologists without disruption.” This platform is installed as a pilot project at The Ohio State University for potential expansion of its digital pathology consultation service. Dr. Parwani has no personal conflicts of interest to disclose. About PathPresenter PathPresenter is the world’s most widely used digital pathology platform, with a community of more than 40,000 users in 172 countries and 20+ institutional licenses. Our educational and conference module provides a seamless environment for pathologists, radiologists, clinicians, and life science researchers to use, share and collaborate with fellow clinicians throughout the world to learn, teach, present, perform research, and practice better medicine, while connecting industry to a global community of clinicians and researchers. Get started with PathPresenter, for free, at https://pathpresenter.net/. Our new ClinPX TM clinical enterprise platform helps hospitals and labs expand the reach of their clinical consultation (2 nd opinion) services globally, increase their efficiency, and optimize the user experience for both consulting pathologists and client pathologists. Through deep integration with the institution’s existing laboratory information system (LIS), consulting pathologists can receive, view, and sign out cases uploaded from around the world directly in the LIS. ClinPX allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists in addition to bidirectional communication channels for ordering stains and recuts. Further, it enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. Through a robust API, ClinPX integrates with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate. Contact Details PathPresenter Cory Batenchuk - SVP of Operations +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.net

April 13, 2022 11:00 AM Eastern Daylight Time

1 ... 188 189 190 191 192 ... 249